Spyre Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Turtle Cameron | Chief Executive Officer | Sale | 10,995 | $28.73 | $315,886 | 690,912 | Dec 1, 2025 |
| Turtle Cameron | Chief Executive Officer | Sale | 16,845 | $23.66 | $398,553 | 701,907 | Nov 3, 2025 |
| Burrows Scott L | Chief Financial Officer | Sale | 18,428 | $16.26 | $299,639 | 97,994 | Sep 2, 2025 |
| HENDERSON MICHAEL THOMAS | — | Other | 105,379 | — | — | 105,379 | Jan 10, 2025 |
| Albers Jeffrey W. | — | Sale | 6,700 | $36.76 | $246,292 | 27,360 | Nov 6, 2024 |
| Albers Jeffrey W. | — | Sale | 300 | $36.43 | $10,929 | 34,060 | Oct 25, 2024 |
| Burrows Scott L | Chief Financial Officer | Sale | 18,531 | $28.17 | $522,018 | 116,422 | Sep 3, 2024 |
| Harwin Peter Evan | — | Option Exercise | 3,639,680 | — | — | 4,018,101 | Apr 25, 2024 |
| Turtle Cameron | Chief Executive Officer | Award / Grant | 400 | $9.82 | $3,928 | 746,907 | Feb 15, 2024 |
| Fairmount Healthcare Fund II L.P. | — | Other | 3,435,480 | — | — | — | Dec 29, 2023 |
| Burrows Scott L | Chief Financial Officer | Award / Grant | 134,953 | — | — | 134,953 | Dec 22, 2023 |
| Albers Jeffrey W. | — | C | 34,360 | — | — | 34,360 | Nov 24, 2023 |
| Fairmount Healthcare Co-Invest L.P. | — | C | 3,435,480 | — | — | 3,435,480 | Nov 24, 2023 |
| Turtle Cameron | Chief Executive Officer | C | 723,440 | — | — | 746,507 | Nov 24, 2023 |
| Souza Marcio | — | Purchase | 90,000 | $0.56 | $50,400 | 90,000 | Aug 25, 2022 |
| Hanley Jr. Michael Conick | Chief Commercial Officer | Purchase | 28,200 | $0.71 | $20,022 | 36,200 | Jun 8, 2022 |
| Quinn Anthony G. | President & CEO | Purchase | 80,079 | $2.34 | $187,385 | 550,540 | Mar 16, 2022 |
| Quinn Anthony G. | President & CEO | Purchase | 42,417 | $1.86 | $78,896 | 473,461 | Mar 11, 2022 |
| Alspaugh Jonathan | Chief Financial Officer | Purchase | 75,000 | $2.08 | $156,000 | 165,372 | Mar 11, 2022 |
| Shanafelt Armen | — | Purchase | 14,685 | $3.65 | $53,600 | 150,000 | Dec 10, 2021 |
| Quinn Anthony G. | President & CEO | Purchase | 43,108 | $3.70 | $159,500 | 318,269 | Dec 10, 2021 |
| Alspaugh Jonathan | Chief Financial Officer | Purchase | 50,000 | $3.72 | $186,000 | 90,372 | Dec 9, 2021 |
| Quinn Anthony G. | President & CEO | Gift | 175,036 | — | — | 208,845 | Oct 18, 2021 |
| Alspaugh Jonathan | Chief Financial Officer | Purchase | 9,780 | $6.37 | $62,299 | 9,780 | Aug 17, 2021 |
| Quinn Anthony G. | President & CEO | Purchase | 165,000 | $4.75 | $783,750 | 538,469 | Apr 30, 2020 |
| Quinn Anthony G. | President & CEO | Option Exercise | 662 | $5.46 | $3,615 | 354,305 | Oct 4, 2019 |
| Quinn Anthony G. | President & CEO | Purchase | 12,217 | $6.11 | $74,646 | 333,955 | Jun 14, 2019 |
| Quinn Anthony G. | President & CEO | Purchase | 3,809 | $6.86 | $26,130 | 321,738 | May 20, 2019 |
| Quinn Anthony G. | President & CEO | Purchase | 6,218 | $6.65 | $41,350 | 295,146 | May 15, 2019 |
| Quinn Anthony G. | President & CEO | Option Exercise | 7,433 | $6.31 | $46,902 | 276,433 | Feb 6, 2019 |
| Schuchart Aaron | Chief Business Officer | Sale | 5,900 | $9.50 | $56,050 | 2,500 | Sep 27, 2018 |
| Schuchart Aaron | Chief Business Officer | Option Exercise | 8,500 | $3.50 | $29,750 | 8,500 | Aug 17, 2018 |
| GEORGIOU GEORGE | — | Option Exercise | 20,000 | $4.73 | $94,600 | 175,861 | Aug 13, 2018 |
| Quinn Anthony G. | Interim CEO | Option Exercise | 24,000 | $7.04 | $168,960 | 77,927 | Jul 12, 2018 |
| Quinn Anthony G. | Interim CEO | Option Exercise | 3,307 | $5.46 | $18,056 | 53,927 | Jul 11, 2018 |
| Novartis Bioventures Ltd | — | Sale | 19,550 | $10.06 | $196,673 | 2,175,314 | May 11, 2018 |
| Novartis Bioventures Ltd | — | Sale | 22,725 | $10.13 | $230,204 | 2,194,864 | May 9, 2018 |
| NOVARTIS AG | — | Sale | 26,557 | $10.03 | $266,367 | 2,268,819 | May 7, 2018 |
| Quinn Anthony G. | President & CEO | Option Exercise | 150,000 | $4.11 | $616,500 | 245,787 | Feb 15, 2018 |
| Quinn Anthony G. | Interim CEO | Option Exercise | 15,211 | $5.46 | $83,052 | 50,620 | Feb 15, 2018 |
| Quinn Anthony G. | Interim CEO | Purchase | 600 | $5.07 | $3,042 | 35,409 | Dec 6, 2017 |
| York Charles N II | Chief Financial Officer and VP | Purchase | 2,000 | $4.28 | $8,560 | 12,828 | Dec 4, 2017 |
| Quinn Anthony G. | — | Purchase | 5,065 | $4.93 | $24,970 | 27,121 | Dec 1, 2017 |
| ORBIMED ADVISORS LLC | — | Purchase | 30,500 | $5.04 | $153,720 | 1,390,724 | Feb 21, 2017 |
| Cox Russell J. | — | Purchase | 7,000 | $10.00 | $70,000 | 7,000 | Apr 12, 2016 |
| Lowe David George | CEO and President | C | 5,658 | — | — | 5,658 | Apr 12, 2016 |
| NOVARTIS AG | — | Purchase | 300,000 | $10.00 | $3,000,000 | 2,310,924 | Apr 12, 2016 |
| Quinn Anthony | — | Purchase | 10,000 | $10.00 | $100,000 | 10,000 | Apr 12, 2016 |
| TYLER JOSEPH E | VP, Manufacturing | C | 31,260 | — | — | 42,428 | Apr 12, 2016 |
| York Charles N II | Chief Financial Officer and VP | C | 1,324 | — | — | 8,828 | Apr 12, 2016 |